menu search

SRDX / 3 Reasons to Add Surmodics (SRDX) Stock to Your Portfolio Now

3 Reasons to Add Surmodics (SRDX) Stock to Your Portfolio Now
Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business. Read More
Posted: Aug 24 2022, 15:48
Author Name: Zacks Investment Research
Views: 110798

SRDX News  

3 Reasons to Add Surmodics (SRDX) Stock to Your Portfolio

By Zacks Investment Research
October 10, 2023

3 Reasons to Add Surmodics (SRDX) Stock to Your Portfolio

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock. more_horizontal

Surmodics (SRDX) Hits 52-Week High: What's Driving the Stock?

By Zacks Investment Research
September 12, 2023

Surmodics (SRDX) Hits 52-Week High: What's Driving the Stock?

Investors are optimistic about Surmodics' (SRDX) consistent efforts to boost R&D. more_horizontal

Surmodics to Participate in Upcoming Investor Conferences in August

By Business Wire
August 9, 2023

Surmodics to Participate in Upcoming Investor Conferences in August

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Needham--SRDX, a provider of medical device and in vitro diagnostic technologies, announced management will pa more_horizontal

Surmodics, Inc. (SRDX) Q3 2023 Earnings Call Transcript

By Seeking Alpha
August 6, 2023

Surmodics, Inc. (SRDX) Q3 2023 Earnings Call Transcript

Surmodics, Inc. (NASDAQ:SRDX ) Q3 2023 Earnings Conference Call August 2, 2023 8:00 AM ET Company Participants Gary Maharaj - President & Chief Execut more_horizontal

Surmodics (SRDX) Q3 Earnings Top Estimates, FY23 View Up

By Zacks Investment Research
August 3, 2023

Surmodics (SRDX) Q3 Earnings Top Estimates, FY23 View Up

Surmodics (SRDX) reports a solid fiscal third quarter top line on the back of robust Medical Device revenues. more_horizontal

SurModics (SRDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

By Zacks Investment Research
August 2, 2023

SurModics (SRDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to comp more_horizontal

SurModics (SRDX) Surpasses Q3 Earnings and Revenue Estimates

By Zacks Investment Research
August 2, 2023

SurModics (SRDX) Surpasses Q3 Earnings and Revenue Estimates

SurModics (SRDX) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of a loss of $0.46 per share. This compares more_horizontal

Three Reasons to Add Surmodics (SRDX) Stock to Your Portfolio

By Zacks Investment Research
June 28, 2023

Three Reasons to Add Surmodics (SRDX) Stock to Your Portfolio

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock. more_horizontal


Search within

Pages Search Results: